Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates the low-density lipoprotein (LDL) receptor, elevating LDL cholesterol and accelerating atherosclerotic heart disease, making it a promising cardiovascular drug target. 29259136 2018
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 AlteredExpression disease BEFREE It is an autosomal dominant disease, caused by variants in Ldlr, ApoB or Pcsk9, which results in high levels of LDL-cholesterol (LDL-C) leading to early coronary heart disease. 25839937 2015
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Consequently, the role of PCSK9 in modulating circulating LDL makes it a promising therapeutic target for treating hypercholesterolemia and coronary heart disease. 20172854 2010
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Recent evidence indicates that PCSK9 also modulates the metabolism of triglyceride-rich apolipoprotein B (apoB) lipoproteins, another important coronary heart disease risk factor. 25070550 2014
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE Loss-of-function mutations in PCSK-9 gene invariably translates into lower levels of LDL, and decreased risk of developing coronary artery disease. 30953636 2019
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Our findings provide new insights into LDL biology and show that targeting PCSK9 using heparan sulfate mimetics is a potential therapeutic strategy in coronary artery disease.PCSK9 interacts with LDL receptor, causing its degradation, and consequently reduces the clearance of LDL.Here, Gustafsen et al. show that PCSK9 interacts with heparan sulfate proteoglycans and this binding favors LDLR degradation. 28894089 2017
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. 15893176 2005
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 AlteredExpression disease BEFREE We measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary heart disease and/or type II diabetes (T2D) mellitus. 29103916 2019
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE Loss-of-function mutations in PCSK9 cause familial hypobetalipoproteinemia, which appears to lower risk for coronary artery disease and has no adverse sequelae. 24751931 2014
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 AlteredExpression disease BEFREE Relationship between myocardial ischaemia and PCSK9 expression and autophagy was examined in cultured mouse cardiomyocytes. 29800228 2018
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE To investigate the association of each PCSK9 subtype with coronary atherosclerosis in HeFH. 28502498 2018
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE We confirmed previously observed significant associations between coronary artery disease and low-frequency missense variants in the genes LPA and PCSK9. 26934567 2016
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. 19191720 2009
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE The secondary end points are (1) MACE developed from visit 1 to visit 2 (day 30); (2) MACE developed from visit 2 (day 30) to visit 5 (day 730); (3) treatment rate by lipid-lowering therapies (any statin or intensive, PCSK9 inhibitor, fibrates and ezetimibe); (4) incidence of events by the addition of the following outcomes to the primary end point: coronary revascularisation due to myocardial ischaemia, revascularisation other than coronary artery, inpatient treatment for occurrence or exacerbation of heart failure, transient ischaemic attack, acute arterial occlusion, central retinal artery occlusion and other adverse events prolonging or requiring hospitalisation and (5) proportion of subjects achieving target lipid levels. 28674132 2017
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE This review aims to discuss the impact of natural mutations in the PCSK9 gene on cholesterol metabolism and thus coronary artery disease, as well as molecular mechanisms and therapeutic strategies for PCSK9 inhibition. 24667128 2014
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE Genetic variation in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene has been recently identified as an important determinant of plasma LDL-cholesterol and severity of coronary heart disease. 17940607 2007
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE PCSK9 polymorphism in a Tunisian cohort: identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk. 25239117 2015
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. 31207358 2019
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Background Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to be related to several risk factors and diseases such as inflammatory markers and coronary artery disease. 28166668 2018
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE Serum PCSK9 concentrations are higher in patients with coronary artery lesions, and are associated with SYNTAX and GRACE scores, suggesting that PCSK9 is a potential biomarker of the severity of coronary artery disease. 30112872 2018
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 AlteredExpression disease BEFREE In statin treated asymptomatic FH patients, elevated PCSK9 and Lp(a) levels are independently associated with the presence and severity of CAC, a good predictor of coronary artery disease. 27594539 2016
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE A state transition Markov model was developed to model the cost-effectiveness of PCSK9 inhibitors for prevention of coronary heart disease, ischaemic strokes, and death among high-risk patient subpopulations in Norway, in both primary and secondary settings. 28444187 2018
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE The GLAGOV trial compared the effect of the PCSK9 inhibitor, evolocumab, and placebo on progression of coronary atherosclerosis in patients treated with at least moderate intensity statin therapy. 28937411 2017
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 Biomarker disease BEFREE We conducted a comprehensive search of electronic databases, up to December 1, 2018, for all RCTs comparing PCSK9 inhibition to placebo or ezetimibe in patients with hypercholesterolemia or coronary artery disease receiving maximally tolerated statin for primary or secondary prevention of mortality and cardiovascular outcomes. 31679643 2019
Entrez Id: 255738
Gene Symbol: PCSK9
PCSK9
0.400 GeneticVariation disease BEFREE PCSK9 gain of function mutations cause hypercholesterolaemia by a reduction of LDL receptor levels, while PCSK9 loss of function variants are associated with a reduction of LDL-C values and a decreased risk of coronary heart disease. 18708425 2008